The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A10 | Drugs used in diabetes | |
3
|
A10X | Other drugs used in diabetes |
| Code | Title | |
|---|---|---|
| A10XX | Other drugs used in diabetes |
| Active Ingredient |
|---|
|
Teplizumab binds to CD3 (a cell surface antigen present on T lymphocytes) and delays disease progression in patients with stage 2 T1D. The mechanism may involve partial agonistic signalling leading to deactivation of autoreactive CD8+ T lymphocytes and reduced immune-mediated beta-cell destruction. Teplizumab leads to an increase in the proportion of CD8+ T cells with signs of exhaustion in peripheral blood. |
| Document | Type | Information Source | |
|---|---|---|---|
| TZIELD Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |